Significant progress has been made in the science and regulation of biosimilar development and approval, while awareness and educational efforts have increased prescriber and patient confidence and uptake. Join DIA's Biosimilars Conference, held virtually, October 6-7, where manufacturers, regulators, payers, prescribers, and patients will convene to share perspectives on success and equilibrium and to envision the biosimilars landscape for the coming years.